Montrouge, France, September 9, 2020
DBV Applied sciences Publicizes Management Modifications
DBV Applied sciences (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Inventory Market: DBVT), a clinical-stage biopharmaceutical firm, at present introduced that Ramzi Benamar, Chief Monetary Officer, and Kevin Trapp, Chief Industrial Officer, can be leaving the Firm as of October 2, 2020.
Sébastien Robitaille has been appointed as Chief Monetary Officer efficient October 2, 2020. Mr. Robitaille joined DBV in 2015 as Senior VP, Group Controller and Info Techniques, was subsequently named Chief Transformation Officer and Deputy Chief Monetary Officer in 2017, earlier than being promoted to Chief of Workers to the CEO in 2019.
“Sébastien can be invaluable to DBV in his function as Chief Monetary Officer given his deep understanding of our enterprise and his function in driving our execution, in addition to his tenure as Deputy Chief Monetary Officer,” mentioned Daniel Tassé, DBV’s Chief Govt Officer. “He has demonstrated expertise in main the Firm by way of durations of transition, and we consider his confirmed acumen will serve him nicely on this new capability.”
“On behalf of the complete group, I want to thank Ramzi and Kevin for his or her vital contributions to DBV,” mentioned Mr. Tassé. “Ramzi strengthened the DBV stability sheet in preparation for potential industrial launch and can go away the Firm in a powerful money and monetary place. Kevin constructed a strong industrial group and developed a launch technique for Viaskin Peanut, if permitted. I want them good luck of their upcoming endeavors.”
On August 4, 2020, the Firm introduced that it had acquired a Full Response Letter from U.S. Meals and Drug Administration (FDA) for its Biologics License Utility (BLA) for investigational Viaskin™ Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to deal with peanut allergy symptoms in kids ages Four to 11 years. The Firm is getting ready a gathering request to the FDA.
About DBV Applied sciences
DBV Applied sciences is growing Viaskin™, an investigational proprietary know-how platform with broad potential functions in immunotherapy. Viaskin is predicated on epicutaneous immunotherapy, or EPIT™, DBV’s technique of delivering biologically lively compounds to the immune system by way of intact pores and skin. With this new class of non-invasive product candidates, the Firm is devoted to securely remodeling the care of meals allergic sufferers. DBV’s meals allergy symptoms applications embody ongoing medical trials of Viaskin Peanut and Viaskin Milk, and preclinical improvement of Viaskin Egg. DBV can be pursuing a human proof-of-concept medical trial of Viaskin Milk for the remedy of Eosinophilic Esophagitis, and exploring potential functions of its platform in vaccines and different immune illnesses. DBV Applied sciences has world headquarters in Montrouge, France and places of work in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Firm’s bizarre shares are traded on phase B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), a part of the SBF120 index, and the Firm’s ADSs (every representing one-half of 1 bizarre share) are traded on the Nasdaq World Choose Market (Ticker: DBVT).
Ahead Trying Statements
This press launch might include forward-looking statements and estimates, together with statements relating to the potential advantages of Viaskin Peanut and anticipated regulatory interactions. These forward-looking statements and estimates usually are not guarantees or ensures and contain substantial dangers and uncertainties. At this stage, the Firm’s merchandise haven’t been licensed on the market in any nation. Among the many elements that might trigger precise outcomes to vary materially from these described or projected herein embody uncertainties related usually with analysis and improvement, medical trials and associated regulatory evaluations and approvals, together with the impression of the COVID-19 pandemic. Moreover, the timing of any motion by the FDA and potential regulatory paths ahead can’t be assured. An extra listing and outline of those dangers, uncertainties and different dangers could be discovered within the Firm’s regulatory filings with the French Autorité des Marchés Financiers, the Firm’s Securities and Trade Fee filings and experiences, together with within the Firm’s Annual Report on Type 20-F for the yr ended December 31, 2019, and future filings and experiences by the Firm. Current and potential traders are cautioned to not place undue reliance on these forward-looking statements and estimates, which communicate solely as of the date hereof. Apart from as required by relevant legislation, DBV Applied sciences undertakes no obligation to replace or revise the data contained on this Press Launch.
Investor Relations Contact
+ 1 (857) 529-2363
+1 (646) 842-2393